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Abstract Arrhythmogenic cardiomyopathy, or its most
well-known subform arrhythmogenic right ventricular car-
diomyopathy (ARVC), is a cardiac disease mainly charac-
terised by a gradual replacement of the myocardial mass
by fibrous and fatty tissue, leading to dilatation of the
ventricular wall, arrhythmias and progression towards heart
failure. ARVC is commonly regarded as a disease of the
intercalated disk in which mutations in desmosomal pro-
teins are an important causative factor. Interestingly, the
Dutch founder mutation PLN R14Del has been identified
to play an additional, and major, role in ARVC patients
within the Netherlands. This is remarkable since the phos-
pholamban (PLN) protein plays a leading role in regulation
of the sarcoplasmic reticulum calcium load rather than in
the establishment of intercellular integrity. In this review
we outline the intracellular cardiac calcium dynamics and
relate pathophysiological signalling, induced by disturbed
calcium handling, with activation of calmodulin dependent
kinase II (CaMKII) and calcineurin A (CnA). We postulate
a thus far unrecognised role for Ca2+ sensitive signalling
proteins in maladaptive remodelling of the macromolecular
protein complex that forms the intercalated disk, during
pro-arrhythmic remodelling of the heart.
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Genetic causes of cardiomyopathy
Over the last decades, multiple studies have identified over
100 genes and mutations involved in various forms of car-
diac disease such as hypertrophic, dilated, and arrhythmo-
genic cardiomyopathy (HCM, DCM, and ACM, respec-
tively) [1]. These genes mainly encode proteins of the con-
tractile machinery, but also proteins that participate in cal-
cium homeostasis and ones that reside in the intercalated
disk (ID). As a consequence, mutations in these genes
have pathogenic effects on several cardiac cellular func-
tions, such as contractile force generation, force regulation,
signal transduction, excitability and intracellular calcium
handling. Since the discovery of the first causative muta-
tions for cardiomyopathies, attention for such inherited ge-
netic disorders has greatly increased. To uncover the conse-
quences of these genetic mutations contributes importantly
to knowledge of the underlying pathogenic mechanisms and
has introduced a regimen of clinical genetic evaluation of
affected individuals and their relatives. Early identification
of asymptomatic mutation carriers, via genetic screening,
is of major prognostic importance since cardiomyopathies,
with an emphasis on ACM, can lead to sudden cardiac death
as a result of malignant ventricular arrhythmias even before
the onset of any symptoms.
Interestingly, there are multiple genes in which genetic
aberrancies cause different types of cardiomyopathies and
even opposite functional effects are present. For example,
mutations in proteins involved in calcium handling, such
as phospholamban (PLN), which mostly correlate to DCM
also manifest in the setting of ACM [2]. On the other hand,
mutations in the gene encoding the desmosomal protein
plakophilin2 (PKP2) are classically correlated with ARVC
(a subform of ACM), [3] but can additionally be identi-
fied in DCM patients [4]. Likewise, mutations in PKP2 are
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also present in patients suffering from Brugada syndrome,
a disease commonly related to mutations in multiple ion
channels instead of desmosomal proteins [5]. These studies
suggest that distinct cardiac proteins should not be con-
sidered to be completely autonomous working entities, but
rather that they function in different macromolecular pro-
tein complexes. In this review we will focus specifically on
gene mutations that relate to ACM and the potential mech-
anisms that drive proarrhythmic cardiac remodelling in this
disease. For a subset of these mutations, particularly those
involving PLN, we postulate a potential role for calcium
sensitive signalling pathways.
Pathophysiological remodelling in arrhythmogenic
cardiomyopathy
During cardiomyopathy, not exclusively limited to ARVC,
ventricular arrhythmias can arise out of electrical and struc-
tural cardiac remodelling, which disrupts cell-cell commu-
nication, excitability and the pump function of the heart [6].
Electrical remodelling is based on abnormal expression, dis-
tribution and regulation of ion channels and gap junctions,
and a heterogeneous expansion of the extracellular matrix
(fibrosis formation) which results in a disturbed electrical
cell-cell signalling between cardiomyocytes or between car-
diomyocytes and (myo)fibroblasts [6, 7]. Increased patho-
physiological intracellular calcium concentrations, caused
by dysfunction of calcium regulatory proteins, negatively
affects the contraction and relaxation dynamics of the heart
(reviewed by ‘Qu et al. 2015’) [6]. Structural cardiac remod-
elling involves myocyte death, fibre disorders, changes in
cell size (hypertrophy), and collagen deposition (fibrosis).
Structural remodelling disturbs the impulse propagation be-
tween cardiomyocytes and hampers pump function of the
entire heart [6].
ARVC, the most familiar form of ACM, is a cardiac dis-
ease mainly characterised by a gradual replacement of the
myocardial mass by fibrous and fatty tissue, which causes
dilatation of the ventricular wall and progression towards
heart failure. As such, this is classically defined as structural
remodelling, but it also includes a disruption of proper elec-
trical signalling, with a high susceptibility for ventricular
arrhythmias. As described in several studies, remodelling
also results in a combination of reduced sodium channel
(Nav1.5), gap junction channels (constituted of connexin43,
Cx43) and plakoglobin localisation at the ID of patients [8].
ARVC is a familial disease with an estimated frequency of
1:5000 people all over the world, though in some regions
prevalence is more pronounced [9]. In about 60% of the
ARVC cases, a mutation is the underlying cause of the
disease [2]. Mutations in genes encoding the desmosomal
proteins PKP2, plakoglobin (gene name JUP), desmoplakin
(DSP), desmocollin-2 (DSC2) and desmoglein-2 (DSG2),
are highly related to development of ARVC [1]. Those mu-
tations are predominantly found in the PKP-2 gene, but
have also been discovered in genes encoding non-desmo-
somal proteins such as ryanodine receptor2 (RYR2), trans-
forming growth factor β3 (TGFβ3), lamin A/C (LMNA),
transmembrane protein 43 (TMEM43), desmin (DES), titin
(TTN), αT-catenin (CTNNA3) and PLN [1].
The fact that mutations in genes encoding desmosomal
and non-desmosomal proteins commonly lead to a compa-
rable clinical phenotype suggests that more than one under-
lying mechanism could be involved in the process of cardiac
remodelling in ARVC patients. This is strengthened by the
identification of a role for mutations in the sarcoplasmic
reticulum (SR) associated proteins PLN and RYR2, and
the fact that in the other 40% of patients diagnosed with
ARVC, no causative mutations, or mutations not yet linked
to ARVC, have been detected thus far [1]. PLN is a trans-
membrane SR phosphoprotein and a key regulator of cal-
cium homeostasis. As expected, mutations in PLN mostly
lead to inhibition of the calcium re-uptake into the SR [10].
Interestingly, next to the classical desmosomal mutations
that trigger instability of the ID (potentially due to traffick-
ing defects), the pathogenic PLN-R14Del mutation is iden-
tified in patients diagnosed with ARVC. In such patients,
a differential diagnosis of DCM or ARVC can be made [2].
In the Netherlands, the PLN-R14Del mutation is a founder
mutation and has been identified in 10–15% of patients di-
agnosed with either DCM or ARVC [11]. This similarity
in pathophysiological remodelling driven by dysfunction/
mislocalisation of proteins in the ID and proteins related
to the intracellular calcium handling may perhaps not be
as long distance as it seems at first glance. Present studies
provide an interesting new view into the possible interac-
tion between structures classically defined as separate (ID
and calcium homeostasis). Next to the well-known classical
model, based on malfunctioning/mislocalised desmosomal
proteins, also involvement of alternative mechanisms under-
lying ARVC phenotype should be mentioned. The canon-
ical Wnt/β-catenin signalling pathway and hippo pathway
illustrate pathways which are affected by ID proteins un-
der pathogenic conditions, ending in recapitulation of the
ARVC phenotype [12, 13]. In this regard, the common ob-
servation that plakoglobin signals are reduced or even ab-
sent at the ID is important [8, 14], while glycogen synthase
kinase 3β (GSK3β) seems to accumulate at the ID during
pathological remodelling [15].
Cross talk within the intercalated disk
To withstand the strong and frequent mechanical forces of
the beating heart, individual cardiomyocytes tightly con-
Neth Heart J (2017) 25:157–169 159
nect to each other via a subcellular domain named the ID
[14]. IDs are of major physiological importance as they
not only physically connect cardiomyocytes by means of
desmosomes and adherence junctions, but also couple car-
diomyocytes electrically to ensure fast propagation of elec-
trical signals, through gap junctions [14]. Gap junctions are
agglomerates of multiple intercellular channels that con-
sist of two connexons (hemi channels), which are engag-
ing structures composed of hexametric clusters of connexin
proteins, delivered by cells on both sides of each junction. In
the working myocardium, these channels are predominantly
composed of connexin40 (Cx40, atria) and Cx43 (atria and
ventricles). Electrical coupling depends on the organisation
of gap junctions at the ID, whose abundance, resistivity and
distribution defines the characteristics of electrical impulse
propagation between cardiomyocytes. The classical outlook
of the arrangement at the ID with its separated structures
such as desmosomes, gap junctions, ion channels and con-
nexons, is currently changing. Knowledge about the relation
between different structures of the ID is expanding in detail
and it is becoming more and more clear that the ID in fact
is a complex and sophisticated protein network.
Accumulating experimental evidence supports the idea
that the ID should be considered to be a singular arranged
functional entity in which macromolecular complexes me-
chanically and electrically interact in synchrony [16]. This
is exampled by the fact that the loss of desmosomal in-
tegrity, caused by PKP2 dysfunction, leads to a reduced
sodium current (INa), aiding an interaction between the
desmosome and sodium channel complex [5]. This in-
teraction could partly be related to disturbed trafficking
of proteins to the ID. A study by Sato et al. presented
colocalisation of Nav1.5 (the alpha-subunit of the sodium
channel) with PKP2 [17], whereas a very recent study of
the same group identified colocalisation of these sodium
channels with N-cadherin, a protein of the adherence junc-
tion [16]. When PKP2 expression was decreased through
RNA silencing in neonatal rat ventricular myocytes, this
also resulted in a decrease of the total Cx43 content and
a significant redistribution of Cx43 to the intracellular
space. Multiple experiments showed that Cx43 and PKP2
coexist in the same macromolecular complex. Besides this,
ankyrin-G (encoded by ANK3) shows to be a key com-
ponent of linkage within the ID as it is related to three
complexes often considered independent: the voltage-gated
sodium channel, gap junctions, and the cardiac desmosome
[17, 18]. The intermolecular interactions between proteins
relevant to mechanical junctions, and those that constitute
gap junctions/sodium channels embeds important impli-
cations for the pathophysiology of inherited arrhythmias,
such as in ACM [17]. This specifically accounts for patients
in which the ACM is caused by mutations in desmosomal
proteins. However, it is more complex to understand why
patients show a similar clinical phenotype when causative
mutations are present in non-desmosomal proteins such as
PLN, a protein heavily involved in calcium homeostasis.
Certainly if we bear in mind that also in these patients pro-
arrhythmic remodelling of the ID is reported [11, 19].
Calcium dynamics and pathophysiological
signalling
PLN plays a leading role in cardiac excitation contraction
coupling which relies on tightly regulated calcium fluxes
that are triggered when an action potential enters from ad-
jacent cells. Voltage gated L-type calcium channels (LTCC)
on the cell membrane of striated muscle cells open and cal-
cium enters the cell. This influx of calcium into the cell
subsequently triggers opening of RYR2, leading to a co-
ordinated efflux of calcium out of the SR. Local calcium
peaks result in binding of calcium ions to the troponin com-
plex, which consists of three regulatory proteins that form
a contractile complex. If calcium ions unbind from tro-
ponin the myofilaments are able to relax again. Calcium is
removed out of the cardiomyocytes by Na+/Ca2+ exchange
channels (NCX) at the cell membrane or stored back in
the SR by sarco/endoplasmic reticulum Ca2+-ATPase chan-
nels (SERCA, reviewed by ‘Luo et al., 2013’) [20]. The
open and closed state of gap junction/ion channels and
channels involved in calcium handling is tightly controlled
by phosphorylation and dephosphorylation, through kinases
and phosphatases. Under physiological conditions their ac-
tivation is mainly regulated by protein kinase A (PKA), pro-
tein kinase C (PKC), and mitogen-activated protein kinase
signalling. Downstream activity of protein kinases such as
PKA and PKC regulates Ca2+ homeostasis by phosphoryla-
tion of Ca2+ channels, such as LTCC, SERCA, and RYR2.
This regulation is important to adapt to changing demands
as, for example, an elevated cardiac output. Dephosphory-
lated PLN interacts with SERCA and inhibits Ca2+ pump
activity into the SR [10]. By phosphorylation of PLN upon
β-adrenergic stimulation and enhanced cyclic AMP-depen-
dent protein kinase A (PKA) activity, the inhibitory effect of
PLN on SERCA is relieved. This leads to increased initial
rates of SR Ca2+ uptake, accelerated relaxation, enhanced
SR Ca2+ load and increased Ca2+ release by RYR2 during
systole [21].
Under pathophysiological conditions, functional control
of cellular excitability and excitation-contraction coupling
shifts from kinases such as PKA and PKC towards calmod-
ulin dependent kinase II (CaMKII) and calcineurin A (CnA)
[22, 23]. Under pathological conditions the diastolic cal-
cium levels can become persistently higher, which in the
end compromises pump function through insufficient re-
laxation and a reduced force of contraction due to lower































































Fig. 1 Overview illustrating the pro-arrhythmic interactions between Ca2+-sensitive proteins, intercalated disk proteins and ion channels. SR sar-
coplasmatic reticulum, RyR ryanodine receptor, SERCA SR Ca2+ ATPase, PLN phospholamban, LTCC L-type Ca2+ channel, NaL late sodium cur-
rent, NCX Na+/Ca2+ exchanger, NKA Na+/K+-ATPase, AnkG ankyrin-G, DSC2/DSG2 desmocolin-2/desmoglein-2, PKP2 plakophilin-2, Cx43 con-
nexin43, N-Cad N-Cadherin, CaMKII Ca2+/calmodulin-dependent protein kinase II, CaM calmodulin, CnA calcineurin A, EB-1 end-binding pro-
tein 1, NFAT nuclear factor of activated T-cells, CACNA1D voltage-dependent L-type calcium channel subunit alpha-1D, ATP2A2 sarcoplasmic/
endoplasmic reticulum calcium ATPase 2, SCN5A sodium channel protein type 5 subunit alpha, Col1A1/1A2/3A1 alpha-1 type I/1 type 2/3 type 1
collagen, TGFβ1 transforming growth factor beta 1, CTGF connective tissue growth factor, TIMP1 metallopeptidase inhibitor 1
calcium availability during systole [20]. Diastolic calcium
concentrations do not solely rely on LTCC and SR Ca2+
regulation, since alterations in the kinetics of sodium chan-
nels (triggering late sodium current, INa-L), NCX and PLN
activity are also of importance [10, 24]. An increase in
the amplitude of INa-L prolongs the action potential dura-
tion, increases the transmural dispersion of repolarisation
which triggers arrhythmogenesis [25]. An increase in INa-L
also increases the intracellular sodium concentration and
subsequently raises [Ca2+]i via the reverse-mode NCX [26].
Besides affecting kinases and phosphatases such as
CaMKII and CnA, the intracellular calcium concentra-
tion is also capable of affecting the ID structure directly.
Although it is known that elevating intracellular calcium
conditions from very low towards the physiological state
causes targeting and maturation of desmosomes from the
endoplasmic reticulum to the cellular membrane [27], cur-
rently it is still unknown whether such influences can also
be triggered by a persistently elevated diastolic calcium
level above the physiological concentration. Importantly,
the signal transduction pathways induced under persistently
elevated calcium levels further trigger cardiac remodelling
and electrical and contractile modifications [24]. In the
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Ca2+ concentrations, activation of CaMKII and CnA, and
electrical and structural cardiac remodelling in the setting
of ACM (Fig. 1).
Phospholamban dysfunction
Deregulated intracellular Ca2+ handling in cardiomyocytes
is frequently attributed to impaired SR functioning, lead-
ing to heart failure, in which dysfunction of the different
key proteins involved can each be causative. Dysfunction of
PLN has been reported to play a key role in cardiac patho-
physiology and up to now several different mutations have
been identified in patients [21]. Characterisation of those
PLN mutations generally revealed disruption of intracellu-
lar calcium handling, precipitating clinical manifestations
of ACM, DCM and heart failure (see Table 1).
Of special attention in this review is the PLN-R14Del
mutation since this mutation is known to trigger develop-
ment of ACM in patients [19]. PLN is a phosphoprotein
which, when dephosphorylated, inhibits the Ca2+ affinity of
SERCA. PLN phosphorylation can take place at the Ser16
by PKA (during sympathetic stimulation) or at Thr17 by
CaMKII (predominantly during pathophysiological condi-
tions), which reverse the inhibitory effect on SERCA [28].
The PLN-R14Del mutation is associated with the deletion
of the highly conserved basic amino acid Arg-14 in the
coding region. As a result, phosphorylation is still possible
but the inhibitory effect is no longer relieved. Coexpression
of wild-type PLN and mutant PLN-R14Del, in human em-
bryonic kidney (HEK) cells confirmed the super inhibition
of the SERCA channel [10]. This super inhibitory effect
is likely caused by partial destabilisation of the PLN pen-
tamer, leading to production of highly inhibitory monomers
and a persistent PLN-SERCA association. The dominant
inhibitory effect of this mutant was not alleviated by phos-
phorylation through PKA, leading to ventricular dilatation,
contractile dysfunction and ventricular arrhythmias. Trans-
genic mice, overexpressing the PLN-R14Del protein, reca-
pitulated the human cardiomyopathy and resulted in prema-
ture death. Next to the disturbance in Ca2+ transients, PLN-
R14Del patients also show classical ARVC-like features
as fibrofatty replacement and myocardial disarrangement
[10]. A study in endomyocardial samples taken from PLN-
R14Del patients showed depressed or absent plakoglobin
levels indicative of remodelling of the ID in 71% of the
cases [11].
In addition to abnormalities in Ca2+ transients and elec-
trical instability, in cardiomyocytes derived from human
induced pluripotent stem (iPS) cells that were generated
from patients bearing the PLN-R14Del mutation, an ab-
normal distribution of the mutated protein towards the cy-
toplasm was reported [29]. Knocking down the mutated
PLN gene and simultaneous overexpression of a normal
PLN gene (genetic repair) appeared able to reverse this
pathological phenotype in vitro. In a different experimen-
tal mouse model, the mutation was introduced into PLN
null mice, to generate a homozygous PLN-R14Del knock-
out model [21]. Comparable with the situation in PLN-
L39stop mutants, colocalisation of PLN with SERCA was
lost and no inhibition on SR Ca2+ transport and contractility
in these PLN-R14Del mice was present. In contrast, PLN-
R14Del mutated protein misrouted towards the sarcolem-
mal Na+/K+-ATPase (NKA) in the plasma membrane and
stimulated its activity. Eventually these PLN-R14Del mice
showed cardiac remodelling in terms of ventricular dilation
and interstitial fibrosis [21].
The missense mutation at PLN residue 9 (PLN-R9C) has
been reported to cause inherited DCM and heart failure in
patients [30]. Studies in transgenic PLN-R9C mice showed
that the mutated protein did not impair Ca2+ transients by
direct inhibition of SERCA, rather than it depended on trap-
ping of PKA by the mutant protein that resulted in a blocked
PKA-mediated phosphorylation of wild-type PLN. This fi-
nally delayed intracellular calcium transients through super
inhibition of SERCA [30]. A different T116G point muta-
tion resulting in PLN-Leu-39-stop (PLN-L39stop) was also
discovered in familial cases of heart failure [31]. Whereas
the heterozygous mutation caused cardiac hypertrophy, ho-
mozygous patients developed lethal DCM and heart fail-
ure. Homozygous hearts showed a 50% reduction of PLN
mRNA while PLN protein diminished to a negligible level
suggesting that disturbed calcium handling could not be
causative for the disease. Surprisingly, homozygous patients
demonstrated extensive fibrofatty replacement and myocar-
dial disarrangements. In vitro, adenoviral transfection of re-
combinant PLN-L39stop in adult rat cardiomyocytes indeed
confirmed the absence of a maladaptive effect on SERCA
and contractility. Viral transfection of PLN-L39stop in HEK
cells revealed destabilised PLN expression and redirected
minor amounts of PLN towards the cytosol or plasma mem-
branes. This study emphasised a clear contrast between the
disease phenotypes in human and rodents since ablation of
PLN in mice seemed to be beneficial in the setting of heart
failure, whereas human carriers of PLN-L39stop develop
severe and lethal cardiomyopathies [31].
Very recently it was shown that overexpression of PLN-
R25C in adult rat cardiomyocytes extremely suppressed the
affinity of SERCA for Ca2+, resulting in a decreased SR
Ca2+ concentration and Ca2+ transients [32]. Interestingly,
this super inhibition of SERCA caused elevated diastolic
Ca2+ concentrations and CaMKII activation. CaMKII acti-
vation subsequently enhanced RYR2 phosphorylation and
leakage of Ca2+ out of the SR, ending in an impaired cardiac
contractility and ventricular arrhythmias. To further stress
the pivotal role for CaMKII in this pathophysiological re-
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modelling, KN93 inhibition of CaMKII abolished the PLN-
R25C triggered Ca2+ sparks [32].
In general, dysfunctional PLN highly disrupts the car-
diac intracellular calcium handling, finally ending in hy-
pertrophy, DCM, ventricular arrhythmias, heart failure and
premature death. Mainly SERCA, RYR2 and the SR load
are affected, leading to increased diastolic calcium con-
centrations and decreased Ca2+ transients. In spite of the
disturbed calcium homeostasis a subgroup of PLN-R14Del
patients present an ARVC-like phenotype, resembled by
fibro-fatty replacement and ID disarrangement. Compara-
ble alterations were also reported in patients with a differ-
ent PLN mutation, such as PLN-L39stop. The most recent
study also presented an increased CaMKII activation by
PLN-R25C. Several studies in cardiomyocytes have already
proven that increased diastolic Ca2+ concentrations cause
CaMKII auto-phosphorylation and CaMKII activation [22,
33, 34]. Importantly, next to CaMKII, also the Ca2+/CaM ac-
tivated phosphatase CnA is sensitive to increased diastolic
calcium concentrations [23]. In that regard it is of interest to
uncover if a pathophysiological activation of CaMKII and
CnA in ACM patients potentially contributes to the adverse
remodelling in ACM. Because CaMKII and CnA play a key
role in electrical and structural remodelling of the heart, as
postulated in the following paragraphs, it is not unlikely
that also in this particular disease they modulate aspects
of electrical signalling, excitation-contraction coupling and
tissue architecture.
CaMKII in cardiomyopathy
CaMKII and CnA are routinely present in the heart, but
transcription, expression and activation of these proteins is
enhanced during cardiomyopathy [35]. This phenomenon
suggests a pathophysiological role for these proteins in
the development of heart failure. Persistent activation of
beta-adrenergic signalling pathways will activate CaMKII,
but most important, phosphorylation of Ca2+ channels in-
creases the diastolic intracellular Ca2+ concentration, which
facilitates permanent activation of CaMKII via calmodulin
(CaM). Moreover, CaMKII is able to maintain its activated
state independent of calcium-activated CaM via autophos-
phorylation and via the influence of reactive oxygen species
(reviewed by ‘Heineke et al. 2006’) [36]. Amongst many
others, activated CaMKII phosphorylates cardiac proteins
that increase inflammatory signalling and apoptosis [37].
A study in pneumocytes showed that activated CaMKII
drives apoptosis which can lead to pulmonary fibrosis [38].
Chronic pressure overload in a murine knockout model of
CaMKII resulted in a tempered increase in ventricular wall
thickness and no significant levels of fibrosis [22]. Illustra-
tive for its well-studied and maladaptive role in disturbance
of calcium handling, a study in patients with heart fail-
ure suggested that pathophysiologically enhanced CaMKII
levels in cardiomyocytes increased SR Ca2+ leak, which
consequently depleted the SR as Ca2+ store, and decreased
contractility [33]. A link of activated CaMKII to fatty re-
placement, one of the striking hallmarks of remodelling in
ARVC hearts, currently is lacking.
CaMKII remodelling of ID proteins
Beyond its detrimental role in SR calcium handling,
CaMKII can also influence electrical signalling between
cardiomyocytes at the level of the ID, by phosphorylation
of ion channels such as the sodium channel. The CaMKII-
δ isoform stably interacts with two looping domains of the
main cardiac voltage-dependent sodium channel (consti-
tuted from Nav1.5 proteins) and facilitates phosphorylation
at the Ser-516, Ser571 and Thr-594 site [39]. The patho-
logical regulation of cardiac sodium channels by CaMKII
is not well studied in human disease, but animal models of
triggered heart failure presented independent upregulation
of CaMKII levels and enhanced INa during cardiomyopathy
[34]. In dogs with chronic heart failure the INa-L and to-
tal sodium influx levels where enhanced by Ca2+/CaMKII
signalling under physiological and pathophysiological con-
ditions, which was manifested by slowing down of the
inactivation kinetics of the channel [34]. In this model, the
excess of sodium entry was counteracted by activation of
the NCX, which in turn even further enhanced the already
elevated diastolic calcium level. A recent study of Glynn
et al. in mice revealed that phosphorylation of Nav1.5 at
Ser571 regulates the increase in INa-L, but not other channel
properties previously linked to CaMKII [39]. Inhibition
of CaMKII in mice resulted in down regulation of INa,
which negatively affected the sodium channels ability to
depolarise the cell whereas phosphorylation of sodium
channels in rabbit cardiomyocytes delayed the INa recovery
after inactivation and enhance the INa-L [40]. The observa-
tions made in these different models indicate that enhanced
activation of CaMKII increases the depolarising current,
elongating the action potential and thereby increases the
susceptibility to arrhythmias.
Conditional knockout of ankyrin-G in a mouse model
showed that ankyrin-G targets Nav1.5 proteins and its regu-
latory protein CaMKII to the ID for which βIV-spectrin is
necessary [18, 41]. Knockout of ankyrin-G resulted in a de-
creased Nav1.5 expression and membrane trafficking, and
a concomitantly decreased INa and INa-L, highlighting the
dependence of the sodium channel on other protein part-
ners in the ID that serve as a regulatory platform [18, 42].
Moreover, ankyrin-G links sodium channels with broader
ID signalling nodes, as loss of ankyrin-G also resulted in
Neth Heart J (2017) 25:157–169 165
Table 1 Schematic overview of PLN patient mutations, the experimental models used and findings obtained regarding the cardiac pathological
remodelling in human and animals
PLN Mutation Species Mechanism Effect
PLN-R9C muta-
tion [30]


























































[29] IPS-CM Abnormal distribu-
tion PLN to cyto-
plasm




































PLN phospholamban, DCM dilated cardiomyopathy, HF heart failure, PKA protein kinase A, mRNA messenger RNA, PLN-P phosphorylated
PLN, HEK cells human embryonic kidney cells, CM cardiomyocytes; SERCA sarcoplasmic reticulum Ca2+-ATPase, PM plasma membrane,
ARVC arrhythmogenic right ventricular cardiomyopathy, LVW left ventricular wall, iPS-CM induced pluripotent stem cell-derived cardiomyocytes,
NKA Na+/K+-ATPase, ICD implantable cardioverter-defibrillator, CaMKII Ca2+/calmodulin-dependent protein kinase II, HyperP-RYR hyper-phos-
phorylated ryanodine receptor, VA ventricular arrhythmias
reorganisation of PKP2 and lethal arrhythmias in response
to β-adrenergic stimulation [18]. A study by Xu et al. clari-
fied that enhanced cellular calcium entry totally diminished
the open probability of Cx43 gap junction channels which
suggests that gating was affected by a Ca2+/CaM-depen-
dent mechanism [43]. These results reveal that CaM al-
ready links towards gap junctions by itself and additionally
suggest a relation between CaMKII and Cx43. This was
recently confirmed in an in vitro study with cultured car-
diomyocytes, where one novel serine residue in the Cx43
carboxyl terminus was identified that can be phosphorylated
by CaMKII, which suggests that CaMKII may phosphory-
late, and thereby regulates the activity of Cx43 channels in
normal and diseased hearts [44].
Role for calcineurin in fibrosis formation
and conductional remodelling
Calcineurin is a serine-threonine dimeric phosphatase, con-
sisting of the catalytic subunit CnA and the regulatory sub-
unit calcineurin B (CnB). Next to the above described reg-
ulation of CaMKII, Ca2+ saturated CaM directly binds and
activates CnA. Coherent to the fact that CaM needs to be
activated by Ca2+, the amount of CaM needed for activa-
tion of CnA decreases by increasing intracellular calcium
concentrations. Binding and dephosphorylation of nuclear
factor of activated T-cells (NFAT) transcription factors by
CnA in the cytoplasm allows translocation of NFAT into
the nucleus, which induces gene expression of adverse re-
modelling genes. Other kinases such as JNK, p38, GSK3β
and PKA phosphorylate specific NFAT family members

































Fig. 2 Figure illustrating five pathways putatively causing pathological remodelling in ACM: 1) Deficits in EB-1 ID protein trafficking provoke
disturbance of the ID morphology. 2) Pathological activation of the hippo pathway and suppression of Wnt/β-catenin signalling, caused by molecu-
lar remodelling of ID proteins, Plakoglobin nuclear translocation and GSK3β-ID anchoring, recapitulates the ARVC phenotype. 3) Remodelling of
ID proteins by Ca2+-activated CaMKII. 4) Possible direct effect of increased intracellular Ca2+ concentrations on the ID structure. 5) Intracellular
accumulation and degradation of misfolded PLN proteins in PLN-R14Del mutation carriers. GSK3β glycogen synthase kinase 3 beta
and block the nuclear translocation. (Reviewed by ‘Heineke
et al. 2006’) [36].
Activity of CnA was significantly increased in the com-
pensated and decompensated hypertrophic myocardium of
patients with coronary artery disease, and it is suggested
to play a major role in fibrosis formation [45]. Transgenic
mice with a constitutively active form of CnA present in
the myocardium display tremendous deposits of collagen
in the myocardium and show trans-differentiation of ven-
tricular fibroblasts into myofibroblasts, a phenotype known
for its high profibrotic activity [23]. Mice overexpressing
a constitutively active form of CnA presented pathologi-
cal remodelling and impaired Cx43 protein levels. Fontes
et al. studied the postnatal development of mice overex-
pressing this constitutively active form of CnA [46]. After
one week these mice develop cardiac hypertrophy with re-
duced protein and RNA levels of Cx43 and Nav1.5. After
three weeks the protein levels of Cx43 were still reduced
and the connexin proteins were less phosphorylated, poten-
tially as a result of dephosphorylation by CnA. Four weeks
after birth these hearts display substantial levels of fibrosis,
so increased levels of active CnA coincide with reduced ex-
pression of the sodium channel Nav1.5, Cx43 and eventu-
ally end in cardiac hypertrophy and fibrosis formation [46].
In addition, a different transgenic mouse model harbour-
ing an inducible constitutively active CnA gene confirmed
the presented adverse cardiac remodelling, but also indi-
cated reversibility upon block of CnA [47]. CnA inhibition
in a murine CaMKII knockout model confirmed the main
role of CnA in cardiac hypertrophy, associated with fibrosis
formation, apoptosis and systolic dysfunctions.
Neth Heart J (2017) 25:157–169 167
Conclusion and future perspective
ACM, or its most prominent subform ARVC, is commonly
regarded as a disease of the ID in which mutations in
desmosomal proteins are an important causative factor.
Originally described as a composition of separate units,
recent data indicate that the ID should be considered
a single functional unit in which Nav1.5, Cx43, ankyrin-
G and components of the adherence junction and desmo-
some (including PKP2 and plakoglobin) interact. As such,
accumulating evidence in the last decade, suggests that
destabilisation of the ID (through disturbed protein-protein
interactions) and trafficking problems of its composing
proteins trigger the remodelling. The latter aspect was
recently illustrated through deficits in EB-1 ID protein
trafficking causing a disturbed ID morphology resulting
from a disrupted connection between the tubulin network
(which directs the new proteins to the ID) and the existing
macromolecular complex at the ID [48]. Other contributing
mechanisms have recently also acquired more attention as
detrimental roles are anticipated for intracellular accumu-
lation of misfolded or mislocalised protein aggregates, and
alterations in the hippo/Wnt signalling pathways. For the
latter the specific contribution of GSK3β that accumulates
at the ID, and plakoglobin that dispatches from the ID are
topics of investigation (Fig. 2).
The Dutch founder mutation PLN R14Del has been iden-
tified to play a major role in ACM (at least in the Nether-
lands) which seems, as explained, remarkable since PLN is
an important protein involved in regulation of SR calcium
load. Despite of that, patients with this mutation show, be-
yond clinical signs that fit with ARVC, also remodelling of
proteins in the ID and fibrofatty replacement. The mutation
results in dysfunction of PLN and thereby accumulation
of diastolic calcium, which in turn would be able to acti-
vate Ca2+ sensitive proteins as CaMKII and CnA. Patients
with a different PLN mutation, PLN-R25C, indeed show
activation of CaMKII which in the past has been linked
to DCM, heart failure and disturbed calcium handling. As
has been reported for patients with desmosomal mutations,
dysfunction of the cardiac sodium channels is a rather re-
cent observation. Although the experimental proof is still
lacking, if this dysfunction results in enhanced INa-L, also
under these conditions enhanced diastolic calcium levels
can be expected and as such activation of the described
Ca2+-sensitive pathways. Activated CaMKII likely modi-
fies ID proteins, SR structures and ion channels in a direct
fashion, where CnA rectifies their transcriptional regulation
and stimulates formation of fibrosis. In addition, enhanced
cytosolic Ca2+ concentrations can induce autophagy by ac-
tivating CaMKII, a manifestation also seen in PLN-R14Del
patients [49]. Obviously, further experimental investigation
is needed to unravel the exact role of CaMKII and CnA in
ACM.
Step by step, important accomplishments have been
made in our knowledge and understanding. Progression,
however, is sometimes compromised by the fact that the
applied experimental models do not always completely re-
capitulate the situation seen in patients. Obviously patient
material is extremely scarce and often reflects the situation
in the end stage only. Examples of the hurdles that adhere
to experimental models are the fact that calcium handling
in mouse cardiomyocytes, and in cardiomyocytes derived
from iPS cells, is significantly different from that in humans
[50]. Also the important aspect of fibro-fatty replacement,
one of the hallmarks of the disease, is often only partially
recapitulated in mouse models (mostly only the deposi-
tion of fibrosis). Ongoing improvements in experimental
approaches and implementation of new techniques (e. g.
focusing on genetic repair and application of super-resolu-
tion microscopy) provide, however, enough fuel and hope
for a fruitful progression of our aim to control this cardiac
disease.
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